From subgroup analyses, the CSM% of luminal A, luminal B, Her2+, and triple negative were 29.7% (16.5%, 42.8%); 47.2% (19.1%, 75.3%); 59.0% (39.7%, 78.3%); 66.2% (52.8%, 79.6%), respectively.<h4>Conclusions</h4>Breast cancer patients undergoing NAC did not get an ideal odds ratio of CSM. This evidence concerns the gene ERBB2 and breast cancer.